Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine (HCQ) treatment for hospitalized patients with COVID-19

Tsanovska et al., Infectious Disorders - Drug Targets, doi:10.2174/1871526522666220303121209
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 58% Improvement Relative Risk Ventilation 74% ICU admission 70% HCQ for COVID-19  Tsanovska et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? PSM prospective study of 140 patients in Bulgaria (Nov - Dec 2020) Lower mortality (p=0.031) and ventilation (p=0.00066) c19hcq.org Tsanovska et al., Infectious Disorders.., Mar 2022 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
PSM prospective study of 260 COVID-19 patients in Bulgaria, showing lower mortality, ventilation, and ICU admission with HCQ treatment.
risk of death, 57.9% lower, RR 0.42, p = 0.03, treatment 8 of 70 (11.4%), control 19 of 70 (27.1%), NNT 6.4, propensity score matching.
risk of mechanical ventilation, 73.9% lower, RR 0.26, p < 0.001, treatment 6 of 70 (8.6%), control 23 of 70 (32.9%), NNT 4.1, propensity score matching.
risk of ICU admission, 70.4% lower, RR 0.30, p < 0.001, treatment 8 of 70 (11.4%), control 27 of 70 (38.6%), NNT 3.7, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tsanovska et al., 3 Mar 2022, prospective, Bulgaria, peer-reviewed, 8 authors, study period 6 November, 2020 - 28 December, 2020.
This PaperHCQAll
{ 'indexed': {'date-parts': [[2022, 3, 4]], 'date-time': '2022-03-04T07:13:26Z', 'timestamp': 1646378006763}, 'reference-count': 0, 'publisher': 'Bentham Science Publishers Ltd.', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['IDDT'], 'published-print': {'date-parts': [[2022, 3, 3]]}, 'abstract': '<jats:sec>\n' '<jats:title>Objective:</jats:title>\n' '<jats:p>Studies have indicated that hydroxychloroquine (HCQ) exerts antiviral effects against ' 'SARS-CoV-2 in vitro. However, trials regarding its effects in patients are very ' 'controversial. This study aims to evaluate the efficacy of (HCQ) in the treatment of ' 'hospitalized patients with COVID-19.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Methods:</jats:title>\n' '<jats:p>We prospectively enrolled 260 patients hospitalized for COVID-19 in Heart and Brain ' 'Center of Excellence- Pleven, Bulgaria, for the period from November 6 to December 28, 2020. ' 'This study is not randomized, which we compensated for with Propensity Score Matching. ' 'Patients in the HCQ group were given HCQ 200 mg 3 times a day (600mg daily) for the duration ' 'of their hospitalization plus conventional treatment, while those in the control group were ' 'given conventional treatment only. The primary endpoints were transferred to the intensive ' 'care unit, needed for mechanical ventilation, and in-hospital death.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Results:</jats:title>\n' '<jats:p>Of the 260 COVID-19 patients, 178 (68,5%) were male and the mean age was of 63,78 ± ' '12.45 years, with the most prevalent comorbidity hypertension (68,5%). We had two subgroups: ' 'treated with HCQ and conventional treatment (128 patients) and treated with conventional ' 'treatment only (132 patients). In the primary analysis, patients in HCQ group presented with ' 'less comorbidities and were younger than the group without HCQ. Patients treated with HCQ ' 'demonstrated a significant benefit in the primary endpoints compared to those without HCQ, ' 'namely, transferred to ICU – 20 (20,8%) vs 41 (36,9%), p=0,011, need for mechanical ' 'ventilation 13 (13,4%) vs 33 (28,2%), p=0,009 and in- hospital death 14 (10,9%) vs 35 ' '(26,5%), p=0,001, respectively. We repeated this analysis with PSM, where 70 matched pairs ' 'were identified. Regarding the primary endpoints, we found again a statistically significant ' 'difference between the groups. Comparing transferring to ICU, better outcomes were presented ' 'in the HCQ group: 8 (17,4%) vs 27 (44,3%), with p= 0,003. Besides, a smaller proportion of ' 'the patients needed mechanical ventilation: 6 (12,8%), compared to the control group, 23 ' '(35,4%), p= 0,007. Notably, patients from the HCQ group died during hospitalization: 8 ' '(11,4%) in comparison with 19 (27,1%) from the control group, p= 0,018.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Conclusion:</jats:title>\n' '<jats:p>Patients treated with HCQ demonstrated a significant benefit in the primary endpoints ' 'in our study, namely, transfer to the intensive care unit, need for mechanical ventilation, ' 'and in-hospital death. HCQ improves prognosis in hospitalized patients with COVID- ' '19.</jats:p>\n' '</jats:sec>', 'DOI': '10.2174/1871526522666220303121209', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 4]], 'date-time': '2022-03-04T06:46:47Z', 'timestamp': 1646376407000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Hydroxychloroquine (HCQ) treatment for hospitalized patients with COVID- 19.'], 'prefix': '10.2174', 'volume': '22', 'author': [ { 'given': 'Hristina.', 'family': 'Tsanovska', 'sequence': 'first', 'affiliation': [{'name': 'Heart and Brain—University Hospital, Pleven, Bulgaria'}]}, { 'given': 'Iana.', 'family': 'Simova', 'sequence': 'additional', 'affiliation': [ { 'name': 'Heart and Brain—University Hospital, Pleven, Bulgaria | ' 'Bulgarian Cardiac Institute | Medical University, Pleven, ' 'Bulgaria'}]}, { 'given': 'Vladislav', 'family': 'Genov', 'sequence': 'additional', 'affiliation': [{'name': 'Heart and Brain—University Hospital, Pleven, Bulgaria'}]}, { 'given': 'Todor.', 'family': 'Kundurzhiev', 'sequence': 'additional', 'affiliation': [{'name': 'Medical University, Sofia, Bulgaria'}]}, { 'given': 'Jordan.', 'family': 'Krasnaliev', 'sequence': 'additional', 'affiliation': [{'name': 'Heart and Brain—University Hospital, Pleven, Bulgaria;'}]}, { 'given': 'Vladimir.', 'family': 'Kornovski', 'sequence': 'additional', 'affiliation': [{'name': 'Heart and Brain Hospital, Burgas, Bulgaria'}]}, { 'given': 'Nikolai.', 'family': 'Dimitrov', 'sequence': 'additional', 'affiliation': [ { 'name': 'Heart and Brain—University Hospital, Pleven, Bulgaria; | Medical ' 'University, Pleven, Bulgaria | Heart and Brain Hospital, Burgas, ' 'Bulgaria'}]}, { 'given': 'Toni.', 'family': 'Vekov', 'sequence': 'additional', 'affiliation': [ { 'name': 'Bulgarian Cardiac Institute | Medical University, Pleven, ' 'Bulgaria'}]}], 'member': '965', 'container-title': ['Infectious Disorders - Drug Targets'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.eurekaselect.com/article/download/201650', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.eurekaselect.com/201650/article', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.eurekaselect.com/article/download/201650', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 4]], 'date-time': '2022-03-04T06:46:51Z', 'timestamp': 1646376411000}, 'score': 1, 'resource': {'primary': {'URL': None}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3, 3]]}, 'references-count': 0, 'alternative-id': ['LiveAll1'], 'URL': 'http://dx.doi.org/10.2174/1871526522666220303121209', 'relation': {}, 'ISSN': ['1871-5265'], 'issn-type': [{'value': '1871-5265', 'type': 'print'}], 'subject': ['Microbiology (medical)', 'Pharmacology', 'Molecular Medicine', 'General Medicine'], 'published': {'date-parts': [[2022, 3, 3]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit